Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two RNAi-Related Patent Applications: Nov 13, 2008

Premium
Title: RNA Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
 
Number: 20080274989
 
Filed: June 2, 2005 PCT Filed: June 2, 2005
 
Lead Inventor: Beverly Davidson, University of Iowa
 
The invention, the patent application’s abstract states, “is directed to small interfering RNA molecules targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.”
 

 
Title: RNAi Probes Targeting Cancer-Related Proteins
 
Number: 20080274996
 
Filed: May 6, 2008
 
Lead Inventor: Martin Gleave, University of British Columbia (Oncogenex)
 
The patent application, its abstract states, claims “RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma, and melanoma,” as well as Alzheimer's disease.
 
“These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf,” the abstract adds. “The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types … and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual.”